Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

BACKGROUND: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneousl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Capello, Michela, Cappello, Paola, Linty, Federica Caterina, Chiarle, Roberto, Sperduti, Isabella, Novarino, Anna, Salacone, Paola, Mandili, Giorgia, Naccarati, Alessio, Sacerdote, Carlotta, Beghelli, Stefania, Bersani, Samantha, Barbi, Stefano, Bassi, Claudio, Scarpa, Aldo, Nisticò, Paola, Giovarelli, Mirella, Vineis, Paolo, Milella, Michele, Novelli, Francesco
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3844582/
https://ncbi.nlm.nih.gov/pubmed/24010981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-67
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares